



Ventripoint Diagnostics Announces Collaboration with Summit Sciences

Engagement to develop economic and ROI models

Toronto, Ontario (December 18, 2025) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a leader in AI-enhanced cardiac imaging solutions, today announced the engagement of Dana Friesen and Summit Sciences, a specialized consulting firm, to create more sophisticated, customer-centric financial and return-on-investment (ROI) models. This strategic partnership aims to equip healthcare providers with enhanced tools to evaluate the economic benefits of adopting Ventripoint's innovative VMS+ technology for cardiac diagnostics.

The collaboration will focus on refining financial modeling frameworks that highlight the cost savings, operational efficiencies, and clinical outcomes associated with Ventripoint's AI-driven 3D heart modeling system. By integrating advanced analytics and real-world data, the new models will provide tailored insights for hospitals, clinics, and cardiology practices, demonstrating clear ROI through process improvement, better accuracy in heart assessments, and optimized resource allocation.

"We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities," said Hugh MacNaught, President & CEO of Ventripoint Diagnostics. "Dana's extensive expertise in healthcare transformation, combined with Summit Sciences' proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide."

"We believe that Ventripoint's VMS+ system can provide real benefits to patients, healthcare providers, and payors," commented Dana Friesen, CEO of Summit Sciences. "By creating new models based on real-world data, Ventripoint will be able to accelerate the pace of commercializing VMS+ while expanding global access to advanced cardiac imaging. Our history of working in partnership with a variety of partners and delivery models, including indigenous health networks and community-based models of care across Canada, the United States, and Latin America provides experience in delivering culturally sensitive and appropriate solutions addressing cost effectiveness and local accessibility. As an economic research organization, we are equally focused on uncovering both the patient-level outcomes and the measurable financial benefits VMS+™ technology can deliver—ensuring that innovation improves care while strengthening the economic sustainability of healthcare systems."

Dana Friesen brings over 15 years of experience in financial analysis and ROI optimization within the medical device and healthcare sectors. Summit Sciences specializes in delivering

transformational insights and solutions to clients, enabling them to translate complex data into actionable business strategies.

This engagement is part of Ventrifpoint's broader strategy to accelerate market adoption of its VMS+ platform, which uses artificial intelligence to generate accurate 3D models of the heart from standard 2D ultrasound images, offering a faster, more affordable and accessible alternative to traditional MRI scans.

About Ventrifpoint Diagnostics Ltd.

Ventrifpoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventrifpoint's VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventrifpoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

About Summit Sciences

Over the past two decades Summit Sciences has worked with numerous clinical agencies and delivered billions in lifetime partner savings. Summit's research services provide hospitals, manufacturers, and healthcare organizations with the critical data needed to make informed decisions about technology adoption, implementation strategies, and performance optimization. Summit employs advanced research methodologies combining clinical outcome analysis, operational efficiency metrics, and financial impact assessment to deliver actionable insights that improve patient care while optimizing resource utilization and demonstrating clear return on investment.

For further information, please contact:

Hugh MacNaught
hmacnaught@ventrifpoint.com
604-671-4201

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or

statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.